A 43-years old male was admitted to our emergency department complaining of severe dyspnea. He was assigned red code and was admitted directly in shock room. The patient had hystory of asthma (but he used rarely bronchodilators) and he was a drug addict. The patient was conscious but restless, he was unable to lie down, showed signs of respiratory distress with accessory muscle use, he was unable to speak just a single word. Respiratory sounds were diminished on both lungs with severe diffuse and bilateral wheezing. There were no other significative findings to the physical examination. Vital signs were as follows: arterial pressure 145/80 mmHg, heart rate 140 bpm, SpO 2 70% in air. T 36,8°C, respiratory rate 40/min. Promptly, O 2 with reservoire mask was administered; a central venous line was placed in femoral vein because periferal veins were not available. The BGA showed pH 7.14 pCO 2 77 mmHg, pO 2 44.2 mmHg HCO3 28.4 mEq/l, lactate 2.8 mg/dl. The patient was administered nebulized salbutamol, iv metilprednisolone, iv aminophilline, nebulized and im epinephrine, iv magnesium sulphate. Because of the severe respiratory distress and the acute respiratory acidosis, we started also noninvasive ventilation by means of a Draeger Evita 4 ventilator with a facial mask setted as follows: PEEP 0 cmH20 (ZEEP) + ASB 8 cmH20, FiO 2 100%. The patient well tolerated noninvasive ventilation. A chest X-ray showed bilateral lung inflation without pulmonary thickening or pleural effusion; cardiovascular profile was normal. (Figure 1 ).
L'asma bronchiale è una malattia respiratoria cronica caratterizzata da sintomi respiratori di gravità variabile che possono condurre all'insufficienza respiratoria. La NIV è una metodica di supporto respiratorio utilizzata da anni con successo nella BPCO riacutizzata. Tuttavia, il suo uso non è ancora ben definito nelle riacutizzazioni di asma bronchiale. In questo articolo presentiamo la nostra esperienza di un caso di riacutizzazione asmatica quasi-fatale trattata con successo in DEA mediante NIV, ed esaminiamo le evidenze scientifiche al riguardo. SINTESI dl). After 30 minutes of NIV another BGA was performed: pH 7.22, pCO 2 66 mmHg pO 2 453 mmHg HCO3 27.8 mEq/l. Clinically, the patient showed less wheezing and vitals signs were also improving: SpO 2 100% during NIV with FiO 2 1.0, HR 120 bpm R, PA 130/75 mmHg RR 28/min. So, we continued to ventilate the patient as described, reducing FiO 2 from 1.0 to 0.5 because of the excellent pO 2 . After 3 hours of NIV BGA was further improved (pH 7.37, pCO 2 45 mmHg, pO 2 156 mmHg, HCO3 25.4); the patient was therefore transferred in medical ward, where he was administered only O 2 -therapy with nasal cannula, bronchodilators and steroids. He did not need ventilation anymore, and he was discharged the sixth day after admission. Noninvasive ventilation is an effective respiratory support technique, mainly in respiratory insufficiency due to COPD exacerbations. There is increasing evidence that in patient with COPD exacerbation NIV improves blood gas tests while reducing mortality, respiratory workload, and endotracheal intubation needs 1, 3, 4, 5, 6 . Asthma is an inflammatory disease affecting small airways associated with airway hyperresponsiveness, reversible airflow limitation, and respiratory symptoms variabile from dyspnea to status asthmaticus 2 . Asthma shares with BPCO some pathophysiologic features like bronchial airflow limitation, increased respiratory workload and increased residual functional capacity, due to air trapping 2 . However, in asthma these features are mostly reversibile with bronchodilators, while in COPD they are not 2 . Another difference between asthma and COPD is that in latter the airway obstructed are the distal, smallest and more collapsible, while in the former the airway obstructed from mucus are the proximal ones 11 . Besides, in asthmatic patients the airways are stiffer than in COPD patients; so, while airway resistance is higher than in COPD, the dynamic collapse during exhalation may be lower 11 . Therefore, in asthmatic patients there is a higher risk of increasing air trapping by ventilating the patient with external-PEEP without knowing his auto-PEEP 11 . This observation seems to be confermed by some pathophysiologic studies and explains why the authors recommend to ventilate asthmatic patients with zero-PEEP 11, 12, 13 . From a clinical point of view asthma exhacerbations may be divided as follows:
• mild: the patient can walk, lie down and speaks almost normally; he may be agitated and respiratory rate is < 30/min 14 ; • moderate: the patient can not lie down, can say just one sentence; he is agitated, respiratory rate is mildly increased but < 30/min 14 ; • severe: the patient sits up and leans his arms on the table, he is able to speak only a few words, is agitated and respiratory rate is severely increased (> 30/min). When the patient became confuse or disoriented, cardiac arrest is oncoming 14 . In status asthmaticus, death follows asphyxia due to worsening respiratory distress 2 . This is caused by air trapping and decreased ventilation that are followed by hypoxia, hypercapnia and acidosis 2 . Often, in adults, viral upper airways infection are triggers for asthma exhacerbations; however, other known triggers are psychosocial stress, exercise, and allergens 2 . Medical treatment of severe asthma and status asthmaticus is an important challenge for emergency physicians because therapy depends on the patient and on the degree of airflow obstruction. Asthma management includes 2 :
• O 2 -therapy, that should be administered by any means until reaching pO 2 > 60 mmHg and SpO 2 92%; high O 2 flux may be detrimental in hypercapnic patients 2 . • Bronchodilators, that acts on bronchial smooth muscle reducing bronchial obstruction 2 :
1. beta-agonists (mainly short-acting inhaled, like salbutamol); they should be administered by pressurized metered-dose inhalers with spacer; as an alternative, they can be administered by nebulization in O 2 6-8 l/min. Oral or iv way of administration are not more effective, while they increase the risk of side effects (mostly arrhythmic). In severe asthma exhacerbation, beta-agonists therapy should be repeated (2.5-5 mg per dose) every 10-20 min 2 ; 2. anticholinergics. The most effective is inhaled ipratropium bromide administered 80 mcg per dose by means of pressurized metered-dose inhalers with spacer. It can be repeated every 10 min 2 . • Corticosteroids, that act reducing airway inflammation and should be administered by 2 different ways 2 :
1. systemic corticosteroids, may be administered orally or iv; the recommended dose is 40-60 mg prednisone or methylprednisolone 2 . Probably, higher dose (> 160 mg methylprednisolone) are equally effective than lower doses 2 ; 2. inhaled corticosteroids, that seems to increase bronchodilator's effects 2 . • Theophylline. As monotherapy, theophylline is inferior to beta-agonists; however, it can give an additional bronchodilator effect in association to beta-agonists. High incidence of side effects (like tachyarrhytmias) means that it may be useful only in severe asthma. Recommended loading dose is 6 mg/kg iv in 30 minutes followed by 0.5/kg/h until reaching theophylline blood levels 8-12 mcg/ml 2 . • Magnesium sulphate: a safe and cheap medication with some bronchodilator effect. However, 3 recent metaanalysis did not confirm its clinical effectiveness 2, 16, 17, 18 . • Helium. When bronchial obstruction increases, airway flow becomes turbulent, so increasing airway resistance.
Replacing nitrogen with helium (that is more viscous but equally inert) can reduce airway flow turbulence, so decreasing airway resistance. The benefits of heliox (helium + oxygen) are lost when large amounts of supplemental oxygen are introduced into the heliox breathing circuit (FiO 2 > 30% needed to maintain pO 2 > 60 mmHg) 2 .
• Other therapies (leukotriene antagonists, antibiotics)
are not effective per se but may be useful in some selected case 2 . Theoretically, COPD and asthma should respond to non-invasive ventilation in the same way. However, while in COPD the efficacy of non-invasive ventilation is indisputable, there is not yet an agreement on using non-invasive ventilation in asthma. In fact, some studies demostrated that NIV can reduce the need for endotracheal intubation 1 . In a study carried out in 2003, 30 patients were randomized in 2 groups: 15 treated with only conventional therapy, 15 treated with conventional therapy and NIV 7 . After 3 h both groups showed improve-casi clinici emergency care journal -organizzazione, clinica, ricerca • Anno VI numero 3 • Settembre 2010 • www.ecj.it ment in lung function tests (FEV1, FVC, PEF) and BGA parameters, and decreasing in respiratory rate 7 . However, these parameters improve more significantly in patients treated with non-invasive ventilation 7 . In another study, 36 patients admitted to an emergency department were randomized to 3 treatment arms: medical therapy + nebulization, and 2 treatment groups with medical therapy + nebulization + NIV 15 . In the 2 NIV groups, inspiratory pressure was the same, while espiratory pressure was different 15 . The authors of this study noticed that only the group with lower espiratory pressure showed significant clinical improvement 15 . Another observational uncontrolled study showed an improvement of BGA parameters, heart and respiratory rate after NIV in patient with severe asthma exhacerbations 8 . We can find the same results in a study on pediatric patients 9 . These studies suggest that in selected patients NIV may be useful as respiratory support for severe asthma. However, high power studies are lacking and in a Cochrane metaanalysis in 2005 just 1 of the 11 published studies satisfied inclusion criteria 7, 10 . We report a case of a patient admitted for a severe asthma exhacerbation, successfully treated with optimized medical therapy and NIV (zero-PEEP + pressure support). Even if anecdotical, it is not the first described in literature, because some authors described similar cases and some think that NIV may be effective in these patients 6, 7, 8 . Some studies agree with our hypothesis, but they are small-sized and with low statistical power 15 . If these data were confirmed, NIV could prevent endotracheal intubation almost in some selected patient, preventing ICU hospitalization and so decreasing morbidity and costs. Despite that, it is not yet established if NIV could worsen dynamic hyperinflation. Besides, the higher airway resistance of asthmatic patient could make NIV difficult, forcing the physician to increase pressure support, so increasing also air losses and risk of barotrauma. Because of this point of uncertainty, and because of lacking evidence, NIV is not routinely recommended in severe asthma exhacerbations; however, the guidelines do not advise against its use 2, 14 . So, we can conclude that further studies are needed to clarify the role of non-invasive ventilation in asthmatic patients, patients selection criteria and timing compared to invasive ventilation.
